Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388101 | 0.83 | KDM4E (0.50) | CNR2MAOBADORA2AEGLN1 | |
| SCHEMBL1976949 | 0.81 | CNR1 (0.47) | DEGS1MAOBEGLN1 | |
| SCHEMBL16945925 | 0.79 | CNR2 (0.41) | CNR2ADORA2A | |
| SCHEMBL19289588 | 0.79 | TP53 (0.54) | MAOB | |
| SCHEMBL3484342 | 0.78 | DEGS1 (0.45) | CNR2DEGS1 | |
| SCHEMBL13388568 | 0.76 | CHRM2 (0.42) | — | |
| SCHEMBL13388269 | 0.76 | — | — | |
| SCHEMBL2645831 | 0.75 | USP7 (0.50) | DEGS1 | |
| SCHEMBL8282027 | 0.75 | P2RX7 (0.52) | DEGS1MAOB | |
| SCHEMBL5120618 | 0.75 | KMT2A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | CNR2 900/4885DEGS1 4339/4885MAOB 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.